Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6121971 | 0.88 | CTSK (0.44) | CTSKALDH1A1GAATRPM8SMN1; SMN2 | |
| SCHEMBL15239340 | 0.87 | CTSK (0.44) | CTSKRIPK1ALDH1A1GAATRPM8 | |
| SCHEMBL6122567 | 0.87 | CTSK (0.45) | CTSKALDH1A1GAATRPM8CHRM2 | |
| SCHEMBL16762075 | 0.85 | ALDH1A1 (0.46) | CTSKALDH1A1GAATRPM8SMN1; SMN2 | |
| SCHEMBL6123072 | 0.85 | CTSK (0.46) | CTSKALDH1A1GAATRPM8SMN1; SMN2 | |
| SCHEMBL6121764 | 0.85 | CTSK (0.46) | CTSKALDH1A1GAATRPM8SMN1; SMN2 | |
| SCHEMBL16762178 | 0.85 | ALDH1A1 (0.46) | CTSKALDH1A1GAATRPM8SMN1; SMN2 | |
| SCHEMBL6982875 | 0.84 | ALDH1A1 (0.53) | CTSKALDH1A1GAATRPM8SMN1; SMN2 | |
| SCHEMBL21715224 | 0.84 | CTSK (0.67) | CTSK | |
| SCHEMBL31277282 | 0.84 | CTSK (0.67) | CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2640721-A2 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | Texas Heart Institute (US) | 2013-09-25 | — | — | EP | claimed |
| US-20130236434-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE (US) | 2013-09-12 | — | — | US | claimed |
| WO-2012068251-A2 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE (US) | 2012-05-24 | — | — | WO | claimed |
| US-12636274-B2 | Pharmaceutical compositions and methods for systemic treatment of solid tumors | 7 HILLS PHARMA INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-12201686-B2 | Compositions including a therapeutic antibodies and/or a checkpoint inhibitor and an integrin activating compound | 7 HILLS PHARMA INC. (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240189360-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE HOMING AND GRAFTING OF HEMATOPOETIC STEM CELLS | 7 HILLS PHARMA INC. (US) | 2024-06-13 | — | — | US | disclosed |
| US-11484524-B2 | Compositions and methods to improve adoptive cell therapies | 7 Hills Pharma LLC (US) | 2022-11-01 | — | — | US | disclosed |
| CN-107820429-B | Novel compositions and methods for immunotherapy comprising small molecule integrin receptor-ligand agonist adjuvants | 7山药物有限责任公司 | 2022-08-16 | — | — | CN | disclosed |
| US-11311619-B2 | Integrin activator vaccine compositions | 7 Hills Pharma Inc. and Texas Heart Institute (US) | 2022-04-26 | — | — | US | disclosed |
| EP-3104867-B1 | COMPOSITIONS AND METHODS TO IMPROVE THE HOMING AND GRAFTING OF HEMATOPOETIC STEM CELLS | 7 Hills Pharma LLC (US) | 2022-01-19 | — | — | EP | disclosed |
| US-20220001009-A1 | NOVEL COMPOSITIONS INCLUDING A THERAPEUTIC ANTIBODIES AND/OR A CHECKPOINT INHIBITOR AND AN INTEGRIN ACTIVATING COMPOUND | 7 Hills Pharma LLC (US) | 2022-01-06 | — | — | US | disclosed |
| US-20150368234-A1 | AGONISTS THAT ENHANCED BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE | 2015-12-24 | — | — | US | disclosed |
| US-20150291571-A1 | AGONISTS THAT ENHANCED BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE | 2015-10-15 | — | — | US | disclosed |
| US-20150250883-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE HOMING AND GRAFTING OF HEMATOPOETIC STEM CELLS | 7 HILLS PHARMA INC. | 2015-09-10 | — | — | US | disclosed |
| WO-2015123447-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE HOMING AND GRAFTING OF HEMATOPOETIC STEM CELLS | 7 HILLS PHARMA, LLC (US) | 2015-08-20 | — | — | WO | disclosed |
| EP-2881392-A1 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | Texas Heart Institute (US) | 2015-06-10 | — | — | EP | disclosed |
| EP-2881393-A1 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | Texas Heart Institute (US) | 2015-06-10 | — | — | EP | disclosed |
| EP-2640721-A2 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | Texas Heart Institute (US) | 2013-09-25 | — | — | EP | disclosed |
| US-20130236434-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE (US) | 2013-09-12 | — | — | US | disclosed |
| WO-2012068251-A2 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE (US) | 2012-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11311619-B2 | Integrin activator vaccine compositions | ITGAM, ITGA2B, ITGA1 | CTSK 1937/4885RIPK1 3135/4885ALDH1A1 3698/4885 |
| US-11484524-B2 | Compositions and methods to improve adoptive cell therapies | ITGB7, ITGB1, ITGA1 | CTSK 2537/4885RIPK1 4116/4885ALDH1A1 669/4885 |
| US-20220001009-A1 | NOVEL COMPOSITIONS INCLUDING A THERAPEUTIC ANTIBODIES AND/OR A CHECKPOINT INHIBITOR AND AN INTEGRIN ACTIVATING COMPOUND | CD47, ITGB1, ITGAM | CTSK 2541/4885RIPK1 781/4885ALDH1A1 2925/4885 |
| US-12636274-B2 | Pharmaceutical compositions and methods for systemic treatment of solid tumors | CD4, VCAM1, ITGA1 | CTSK 1100/4885RIPK1 2389/4885ALDH1A1 1970/4885 |
| US-20130236434-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | ITGB7, ITGAL, ITGB1 | CTSK 3114/4885RIPK1 4184/4885ALDH1A1 755/4885 |
| US-20150250883-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE HOMING AND GRAFTING OF HEMATOPOETIC STEM CELLS | ITGB7, ITGB1, ITGA1 | CTSK 3822/4885RIPK1 4261/4885ALDH1A1 342/4885 |
| US-12201686-B2 | Compositions including a therapeutic antibodies and/or a checkpoint inhibitor and an integrin activating compound | CD47, CD274, ITGB1 | CTSK 2225/4885RIPK1 949/4885ALDH1A1 2356/4885 |
| US-20150291571-A1 | AGONISTS THAT ENHANCED BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | ITGB7, ITGAL, ITGB1 | CTSK 3030/4885RIPK1 4086/4885ALDH1A1 740/4885 |
| US-20150368234-A1 | AGONISTS THAT ENHANCED BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | ITGB7, ITGAL, ITGB1 | CTSK 3030/4885RIPK1 4086/4885ALDH1A1 740/4885 |
| US-20240189360-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE HOMING AND GRAFTING OF HEMATOPOETIC STEM CELLS | CXCL12, ITGB3, ITGB7 | CTSK 3406/4885RIPK1 4130/4885ALDH1A1 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.